Generalized Anxiety Disorder - Global Clinical Trial Pipeline Highlights, 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Generalized Anxiety Disorder - Global Clinical Trial Pipeline Highlights, 2019" report has been added to ResearchAndMarkets.com's offering.

This report provides most up-to-date information on key pipeline products in the global Generalized Anxiety Disorder market. It covers emerging therapies for Generalized Anxiety Disorder in active clinical development stages including early and late stage clinical trials.

The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages

The report provides Generalized Anxiety Disorder pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes

The report provides Generalized Anxiety Disorder pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company

The report provides Generalized Anxiety Disorder pipeline products by the company.

Short-term Launch Highlights

Find out which Generalized Anxiety Disorder pipeline products will be launched in the US and Ex-US till 2024.

Key Topics Covered

1. Generalized Anxiety Disorder Pipeline by Stages

2. Generalized Anxiety Disorder Phase 3 Clinical Trial Insights

3. Generalized Anxiety Disorder Phase 2 Clinical Trial Insights

4. Generalized Anxiety Disorder Phase 1 Clinical Trial Insights

5. Generalized Anxiety Disorder Preclinical Research Insights

6. Generalized Anxiety Disorder Discovery Stage Insights

7. Appendix

8. Research Methodology

List of Tables

Table 1: Generalized Anxiety Disorder Phase 3 Clinical Trials, 2019

Table 2: Generalized Anxiety Disorder Phase 2 Clinical Trials, 2019

Table 3: Generalized Anxiety Disorder Phase 1 Clinical Trials, 2019

Table 4: Generalized Anxiety Disorder Preclinical Research, 2019

Table 5: Generalized Anxiety Disorder Discovery Stage, 2019

List of Figures

Figure 1: Generalized Anxiety Disorder Pipeline Molecules by Clinical Trials Stage, 2019

Figure 2: Generalized Anxiety Disorder Phase 3 Clinical Trial Highlights, 2019

Figure 3: Generalized Anxiety Disorder Phase 2 Clinical Trial Highlights, 2019

Figure 4: Generalized Anxiety Disorder Phase 1 Clinical Trial Highlights, 2019

Figure 5: Generalized Anxiety Disorder Preclinical Research Highlights, 2019

Figure 6: Generalized Anxiety Disorder Discovery Stage Highlights, 2019

For more information about this report visit https://www.researchandmarkets.com/r/xph15j

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Anxiety Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Anxiety Drugs